LP
AVTX icon

LGL Partners’s Avalo Therapeutics AVTX Stock Holding History

LGL Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$49K – 103
2021
Q4 		$49K Buy
+10
New +$60K 0.01% 113
2021
Q1 		– Sell
-4
Closed -$32K – 91
2020
Q4 		$32K Buy
+4
New +$27.8K 0.02% 90

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

LGL Partners's AVTX Position: Q1 2022 in Review

LGL Partners sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 10 shares — an estimated $49K sold.

LGL Partners first reported a position in AVTX in Q4 2020 and held it in 2 quarters. The position peaked at $49K in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • LGL Partners reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • LGL Partners sold 10 Avalo Therapeutics shares in Q1 2022, an estimated $49K.
  • LGL Partners first reported a position in Avalo Therapeutics in Q4 2020 and held it in 2 quarters.
  • LGL Partners's Avalo Therapeutics position peaked at $49K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on LGL Partners's 13F filing for Q1 2022, filed 16 May 2022.